Oligomerix is an early-stage biotechnology company focused on discovering and developing novel, small molecule tau oligomer inhibitors for AD and related neurodegenerative diseases with tau pathology. The Company’s validated small molecule lead compounds and companion biomarker assays will enable strategic partners to accelerate and de-risk clinical development in the pursuit of DMT for AD. The Company’s tau oligomer inhibitor program includes highly valuable assets such as its screening assays that use full length, non-mutated tau target as found in AD, its CNS drug-like leads, and its translatable biomarker. The Company intends to be a leader in the tau targeting field.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
small molecule tau aggregation inhibitor
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):